KR101936294B1 - Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata - Google Patents
Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata Download PDFInfo
- Publication number
- KR101936294B1 KR101936294B1 KR1020160062854A KR20160062854A KR101936294B1 KR 101936294 B1 KR101936294 B1 KR 101936294B1 KR 1020160062854 A KR1020160062854 A KR 1020160062854A KR 20160062854 A KR20160062854 A KR 20160062854A KR 101936294 B1 KR101936294 B1 KR 101936294B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- skin
- activity
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 241001357959 Hydrangea serrata Species 0.000 title claims description 5
- 240000007001 Rumex acetosella Species 0.000 title description 3
- 235000015761 Rumex acetosella Nutrition 0.000 title description 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 23
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 18
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 18
- 230000002087 whitening effect Effects 0.000 claims abstract description 18
- 230000037303 wrinkles Effects 0.000 claims abstract description 18
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 17
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 235000015110 jellies Nutrition 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- -1 spot Substances 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 10
- 230000006872 improvement Effects 0.000 abstract description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 27
- 230000009182 swimming Effects 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- 230000032683 aging Effects 0.000 description 10
- 230000003078 antioxidant effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000008868 Flower Essence Substances 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241001250103 Paralichthys lethostigma Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000219053 Rumex Species 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241001593968 Vitis palmata Species 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 애기수영 또는 산수국의 추출물을 유효성분으로 함유하는 주름개선 또는 피부 미백용 조성물에 관한 것이다.
본 발명에 따르면, 본 발명의 조성물은 티로시나아제 또는 엘라스타아제를 저해함으로써 피부 주름개선 또는 피부 미백효과를 나타낼 수 있으며, 안전한 소재로서 애기수영 또는 산수국의 추출물은 식품 조성물 분야 또는 화장품 분야에 유용하게 사용될 수 있다.The present invention relates to a composition for improving wrinkles or for whitening skin, which contains an extract of Swine Swine or mountain juice as an active ingredient.
According to the present invention, the composition of the present invention can exhibit skin wrinkle improvement or skin whitening effect by inhibiting tyrosinase or elastase, and as a safe material, Can be usefully used.
Description
본 발명은 주름개선 또는 피부 미백용 조성물에 관한 것으로, 더욱 구체적으로 애기수영 또는 산수국의 추출물을 유효성분으로 함유하는 주름개선 또는 피부 미백용 조성물에 관한 것이다.The present invention relates to a composition for improving wrinkles or skin whitening, and more particularly to a composition for improving wrinkles or skin whitening, which contains an extract of Aji swim or mountain water soup as an active ingredient.
노령인구가 증가함에 따라 노화의 척도가 될 수 있는 피부미용 및 노화를 방지할 수 있는 항산화 분야가 주요 관심사로 떠오르고 있다. 노화로 인한 피부의 주름생성 및 체내의 항산화 활성 감소 등은 건강의 척도로 사용될 수 있다. 피부노화는 요인에 따라 내인성 노화 (Intrinsic aging)와 외인성 노화 (Extrinsic aging)로 구분할 수 있다. 내인성 노화는 나이에 따른 피부 표피 및 진피의 생리적 기능 변화가 원인이며, 외인성 노화는 대기오염, 자외선 노출, 스트레스 등의 환경으로부터 발생하는 피부의 생리적 기능 변화가 원인으로 알려져 있다. 이러한 노화의 공통적 메커니즘은 산화적 스트레스 (Oxidative Stress)에 지속적으로 노출되어 체내의 자유라디칼(Free Radical)이 증가되고, 진피의 결합조직인 엘라스틴 (Elastin)을 분해하는 엘라스타제(Elastase)의 활성증가, 히아루론산 (Hyaluronic acid)을 분해는 히아루론라제(Hyaluronidase)의 활성 증가로 설명될 수 있다. 즉, 피부노화란 피부의 기본적 구조인 엘라스틴 및 히아루론산이 피괴되어 진피를 무너트리고 피부를 건조하게 만들어 주름이 생기는 것으로 설명될 수 있다. 또한, 체내의 라디칼은 멜라닌 형성과정에 관여하여 타이로시나아제(Tyrosinase)를 활성화시켜 기미와 주근깨를 생성하는 원인이 되기도 한다.As the elderly population increases, the beauty of the skin, which can be a measure of aging, and the antioxidant that can prevent aging are becoming a major concern. The generation of wrinkles of the skin due to aging and the reduction of antioxidant activity in the body can be used as a measure of health. Skin aging can be classified into intrinsic aging and extrinsic aging depending on factors. Endogenous aging is caused by changes in physiological functions of skin epidermis and dermis according to age. Exogenous aging is known to be caused by changes in physiological functions of skin caused by environmental pollution, exposure to ultraviolet rays, and stress. The common mechanism of this aging is to increase the free radicals in the body by continuously being exposed to oxidative stress and to increase the activity of Elastase which breaks down the connective tissue of the dermis, Elastin , Degradation of hyaluronic acid (Hyaluronic acid) can be explained by increased activity of hyaluronidase. In other words, skin aging can be explained by the collapse of elastin and hyaluronic acid which are basic structures of skin, collapsing the dermis, making skin dry, and wrinkles. In addition, radicals in the body are involved in the melanin formation process, thereby activating tyrosinase, which causes spots and freckles.
일상생활에서 우리는 활성산소에 의해 일어나는 유해성에 항상 노출되어 있으며, 노화로 인한 유해성은 점진적으로 축적되며 항산화 능력은 점진적으로 감소된다. 일반적인 신체 조건에서 항산화 보호 시스템은 효소(Superoxide dismutase 등) 반응과 비효소(Polyphenols, Flavonoids 등) 반응의 경로로 활성산소를 제거한다. 따라서 항산화 활성을 나타내기 위해서는 SOD와 같은 항산화 효소반응을 활성화 시키거나 직접적인 항산화 작용을 하는 비효소 물질을 섭취해야 한다.In everyday life, we are always exposed to the hazards caused by active oxygen, the aging hazards accumulate gradually, and the antioxidant capacity is gradually reduced. Under normal physical conditions, the antioxidant protection system removes reactive oxygen species through enzymatic (superoxide dismutase, etc.) and non-enzyme (polyphenols, flavonoids, etc.) pathways. Therefore, in order to exhibit antioxidant activity, it is necessary to activate the antioxidant enzyme reaction such as SOD or to take a non-enzyme substance which has a direct antioxidant effect.
이에 따른 피부건강 및 항산화에 대한 기전 연구가 활발히 진행되어 왔으며 생화학적 효능, 효과를 나타내는 화장료 및 건강기능식품에 대한 연구가 진행되고 있다. 연구수준의 발달 및 기술력 증가로 실질적인 효능, 효과를 가진 소재들이 주 연구 대상이다.Therefore, research on the mechanism of skin health and antioxidation has been actively conducted, and researches on cosmetics and health functional foods showing biochemical efficacy and efficacy have been conducted. The main research subjects are materials with practical effects and effects due to the development of research level and the increase of technology.
식물유래 소재는 안전성 측면에서 우수하여 오랫동안 이용되었으며, 특히 국내의 경우, 민간에서 이용되거나 혹은 한방에서 이용되는 식물 및 생약성분을 주로 한 기능성 소재 개발이 활발히 이루어지고 있다.Plant-derived materials have been used for a long time because of their excellent safety, and in particular, functional materials based on plant and herbal ingredients used in the private sector or used in oriental medicine are actively developed.
산수국(Hydrangea serrata)은 범의귀과의 넓은 잎 작은 키 나무로 식약처에서 고시한 식품원재료에 잎 부위가 식용가능부위로 명시되어 있다. 한방에서는 생약명으로 칠엽담이라고 하여 만성기관지염, 지해, 거담, 소염해독 등의 치료에 예로부터 사용되고 있다. 한국공개특허 제2004-0063874호에서는 고혈당 및 고지혈증 억제 활성을 갖는 감차수국 추출물을 함유한 조성물이 개시되었다. Hydrangea serrata is a broad-leaved tall tree of the submandibular gland, and its leaf parts are indicated as edible parts in food raw materials notified in the place of shipment. It is used as a treatment for chronic bronchitis, warts, genomes, and anti-inflammatory drugs. Korean Patent Laid-Open Publication No. 2004-0063874 discloses a composition containing an extract of Oncorhynchospora having hyperglycemia and hyperlipemia inhibitory activity.
애기수영 (Rumex acetosella L.)은 마디풀과에 속하는 식물로 식약처에서 고시한 식품원재료에 어린잎이 식용가능부위로 명시되어 있으며, 한방에서는 잎과 줄기를 약재로 쓰며 주로 항암, 항산화, 이뇨제 및 혈제, 폐결핵 치료에 효과가 있다고 알려져 있다(약초의 성분과 이용, 일월서각. 1994). 한국공개특허 제2005-0056569호에서는 애기수영의 항염, 항산화, 항균작용 기반의 아토피 피부 개선 효과 화장품이 개시되었다.Swim swimming ( Rumex Acetosella L. ) is a plant belonging to the genus Pseudomonas spp., which is indicated as a possible food source in the raw materials of foodstuffs notified by the pet food. The leaves and stems of the leaves are used as medicinal materials and mainly used for anticancer, antioxidant, diuretic, (Use of herbal ingredients and use, Jan., 1994). Korean Patent Laid-Open Publication No. 2005-0056569 discloses a cosmetic for improving atopic skin based on anti-inflammatory, antioxidant, and antibacterial action of swine swimming.
그러나, 애기수영 또는 산수국의 피부 주름개선 또는 피부 미백효과에 대한 직접적인 기전 연구가 이루어지지 않은 실정이다. 따라서 본 발명자들은 상기 추출물들이 가지는 피부 주름 또는 피부 미백에 대한 직접적인 기초 효능 연구를 수행하였다.However, there is no direct research on the mechanism of skin wrinkle improvement or skin whitening effect in swine swimming or mountain sowing. Therefore, the inventors of the present invention conducted a study on the direct basic effects of the extracts on skin wrinkles or skin whitening.
이에, 본 발명자들은 상기 종래기술들의 문제점들을 극복하기 위하여 예의 연구노력한 결과, 애기수영(Rumex acetosella L.) 또는 산수국(Hydrangea serrata)의 추출물을 유효성분으로 함유하는 주름개선 또는 피부 미백용 조성물의 경우, 티로시나아제 또는 엘라스타아제를 저해함으로써 피부 주름개선 또는 피부 미백효과를 나타낼 수 있음을 확인하고, 본 발명을 완성하게 되었다.Thus, the present inventors have made research efforts result, baby swim (Rumex to overcome the problems of the prior art acetosella L. ) or hydrangea serrata as an active ingredient, it may exhibit skin wrinkle improvement or skin whitening effect by inhibiting tyrosinase or elastase. And the present invention was completed.
따라서, 본 발명의 주된 목적은 엘라스타아제 또는 티로시나아제를 저해함으로써 피부 주름개선 또는 피부 미백효과를 갖는 애기수영 또는 산수국의 추출물을 유효성분으로 함유하는 주름개선 또는 피부미백용 조성물을 제공하는 데 있다.Accordingly, it is a main object of the present invention to provide a composition for improving wrinkles or skin whitening comprising an effective amount of an extract of a swine swimming or mountainous soup having skin wrinkle improvement or skin whitening effect by inhibiting elastase or tyrosinase There is.
본 발명의 한 양태에 따르면, 본 발명은 애기수영(Rumex acetosella L.) 또는 산수국(Hydrangea serrata)의 추출물을 유효성분으로 함유하는 주름개선 또는 피부미백용 조성물을 제공한다.According to one aspect of the invention there is provided a baby swim (Rumex acetosella L. ) or an extract of Hydrangea serrata as an active ingredient.
노령인구가 증가함에 따라 노화의 척도가 될 수 있는 피부미용이 주요 관심사로 떠오르고 있다. 피부 미용 중에서도 특히, 주름개선과 피부 미백에 대한 관심이 꾸준히 증가하고 있으며, 이를 개선하기 위하여 많은 건강기능식품과 화장품들의 연구가 활발히 진행되고 있을 뿐만 아니라 이들의 제품이 다양하게 출시되고 있다. 그러나 건강기능식품과 화장품은 직접적으로 섭취하고 피부에 흡수시키는 만큼 안전성 또한 중요한 문제이기 때문에 안전성 측면에서 우수한 식물유래 소재는 꾸준히 이용되고 있다. 이에, 본 발명자들은 천연식물유래 소재 중 애기수영 추출물 또는 산수국 추출물이 피부 주름개선 또는 피부미백 효과가 우수하다는 것을 확인하고 본 발명을 완성하게 되었다.As the elderly population increases, the beauty of the skin, which can be a measure of aging, is becoming a major concern. In particular, the interest in wrinkle improvement and skin whitening has been increasing steadily, and many health functional foods and cosmetics have been actively researched in order to improve them, and their products are being widely launched. However, since health functional foods and cosmetics are directly ingested and absorbed into the skin, safety is also an important issue. Therefore, plant-derived materials superior in safety are being steadily used. Accordingly, the inventors of the present invention have confirmed that the baby swim extract or the mountain water extract of the natural plant-derived material is excellent in skin wrinkle improvement or skin whitening effect, and the present invention has been completed.
본 발명에 있어서, 상기 추출물은 종래에 천연식물을 추출하기 위하여 이용된 어떠한 용매로로 추출될 수 있으며, 바람직하게는 물, 발효주정 또는 이들의 혼합용매로, 더욱 바람직하게는 에탄올로 추출되는 것을 특징으로 한다.In the present invention, the extract can be extracted with any solvent conventionally used for extracting natural plants, preferably water, fermented juice or a mixed solvent thereof, more preferably extracted with ethanol .
본 발명에 있어서, 상기 조성물은 조성물 총 중량대비 0.001 내지 80.0 중량%로 포함할 수 있으며, 바람직하게는 5 내지 20 중량% 포함하는 것을 특징으로 한다. 또한 상기 조건에서 높은 수율과 뛰어난 효소억제 효능을 나타냄을 확인할 수 있었다.In the present invention, the composition may be contained in an amount of 0.001 to 80.0% by weight, and preferably 5 to 20% by weight based on the total weight of the composition. Also, it was confirmed that the above conditions exhibited a high yield and excellent enzyme inhibitory effect.
본 발명에 있어서, 상기 조성물은 엘라스타아제(Elastase)를 저해함으로써 주름개선 효과를 나타내는 것을 특징으로 한다.In the present invention, the composition is characterized by exhibiting an effect of improving wrinkles by inhibiting elastase.
본 발명의 실험예에 따르면, 본 발명의 애기수영 추출물 또는 산수국 추출물의 경우 엘라스타아제 활성 저해율이 양성대조군인 아데노신(Adempsin)과 유사한 범위의 효과를 나타내는 것을 확인하였으며, 본원발명의 조성물이 단일물질이 아닌 추출물이라는 점을 감안할 때, 그 수치는 결코 낮은 것이 아님을 확인할 수 있었다. 이러한 결과로 볼 때, 본원발명의 조성물은 진피의 결합조직인 엘라스틴을 분해하는 엘라스타아제를 저해함으로써, 피부의 주름이 생기는 것을 개선할 수 있음을 알 수 있다(실험예 2 참조).According to the experimental examples of the present invention, it was confirmed that the inhibition rate of the elastase activity in the case of the baby swimming extract or the extract of the acidophilus extract of the present invention showed a similar effect to that of the positive control adempsin (Adempsin) Given that it is an extract that is not a substance, we can confirm that the figure is never low. From these results, it can be seen that the composition of the present invention can improve the appearance of wrinkles of the skin by inhibiting elastase which degrades elastin, which is a connective tissue of dermis (see Experimental Example 2).
본 발명에 있어서, 상기 조성물은 티로시나아제(Tyrosinase)를 저해함으로써 피부미백 효과를 나타내는 것을 특징으로 한다.In the present invention, the composition is characterized by exhibiting skin whitening effect by inhibiting tyrosinase.
본 발명의 실험예에 따르면, 본 발명의 애기수영 추출물 또는 산수국 추출물의 경우 티로시나아제 활성 저해율이 양성대조군인 알부틴(Arbutin)과 유사한 범위의 효과를 나타내는 것을 확인하였으며, 본원발명의 조성물이 단일물질이 아닌 추출물이라는 점을 감안할 때, 그 수치는 결코 낮은 것이 아님을 확인할 수 있었다.이러한 결과로 볼 때, 본원발명은 조성물은 색소침착을 유발하는 멜라닌 생성 과정에 관여하는 효소인 티로시나아제의 활성을 저해함으로써, 피부 미백효과를 나타낼 수 있음을 알 수 있다(실험예 1 참조).According to the experimental examples of the present invention, it was confirmed that the inhibitory activity of tyrosinase activity in the case of the Ajiwa swimming extract or the extract of Sansho sprout of the present invention showed a similar effect to that of Arbutin, which is a positive control group, In view of these facts, the present invention relates to a composition for inhibiting melanin production, which is an enzyme involved in the production of melanin, which causes pigmentation, of tyrosinase It is possible to show a skin whitening effect by inhibiting the activity (see Experimental Example 1).
본 발명에 있어서, 상기 조성물은 정제, 과립제, 환제, 캡슐제, 액상형, 젤리 또는 껌으로 구성되는 군으로부터 선택된 하나 이상의 제형을 갖는 것으로서, 구강 섭취용 인 것을 특징으로 한다.In the present invention, the composition has at least one form selected from the group consisting of tablets, granules, pills, capsules, liquids, jellies or gums, and is characterized in that it is for oral consumption.
본 발명에 있어서, 상기 조성물은 유연화장수, 영양 화장수, 영양 크림, 수분 크림, 스팟, 젤 로션 또는 연고로 구성된 군으로부터 선택된 하나 이상의 제형을 갖는 것으로서, 피부 외용제용 인 것을 특징으로 한다.In the present invention, the composition has at least one formulation selected from the group consisting of a softening agent, a nutritional lotion, a nutritional cream, a water cream, a spot, a gel lotion or an ointment.
이상 설명한 바와 같이, 본원발명의 애기수영 추출물 또는 산수국 추출물을 함유하는 조성물은 엘라스타아제(Elastase), 티로시나아제 (Tyrosinase) 효소를 저해함으로써 피부 주름 개선 또는 피부 미백효과를 나타내어 피부 미용을 위한 조성물로 적합하며, 안전한 소재로서 애기수영 또는 산수국의 추출물을 식품 조성물 분야 또는 화장품 분야에 유용하게 사용될 수 있다.As described above, the composition of the present invention containing the baby swimming extract or the extract of mountain juice extract inhibits elastase and tyrosinase, thereby exhibiting skin wrinkle improvement or skin whitening effect, Composition, and as a safe material, an extract of Swine Swine or Mountain Swine can be usefully used in the fields of food composition or cosmetics.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail with reference to Examples. These embodiments are only for illustrating the present invention, and thus the scope of the present invention is not construed as being limited by these embodiments.
실시예 1: 에탄올을 이용한 추출물의 제조Example 1: Preparation of an extract using ethanol
본 발병의 조성물에 함유되는 애기수영 및 산수국의 추출물은 다음과 같은 과정에 의해 제조된다. 우선, 제주도 내에서 자생하는 1년생 애기수영 및 산수국을 구입하여 증류수로 깨끗이 씻은 다음, 햇빛이 없는 서늘한 곳에서 중량의 변화가 없을 때까지 완전히 건조시켰다. 그 후, 완전히 건조된 건조물을 균질화기를 사용하여 분쇄하여 분쇄물들을 얻은 다음 에탄올 : 증류수를 7 : 3의 중량비로 혼합하여 추출 용매 400g 씩을 준비 한 후, 상기 분쇄물을 각각 50g 씩 첨가하였다. 이때, 분쇄물과 추출용매의 혼합비율은, 중량비로 1 : 8로 하였다. 다음으로, 상기 분쇄물과 혼합한 추출 용매를 진탕 항온 수조에 넣어서 50 ℃, 2시간 동안 교반추출 하였다. 추출에 의해 얻어진 물질은 상온에서 와트만(No 2.) 추출 용매 여과지를 사용하여 불용성 물질을 제거하였다. 그 후, 냉각 콘덴서가 달린 증류장치에서 감압농축 하면서 용매를 완전히 제거하였다. 추출물을 완전히 건조 후 각각의 수율을 측정하였다. 각각의 수율 측정 결과 애기수영은 5.82%, 산수국은 20%를 나타내었다.The baby swim and the extract of the mountaineering soup contained in the composition of the present invention are produced by the following process. First of all, the first year baby swimming and mountain juice native to Jeju Island was purchased, washed thoroughly with distilled water, and completely dried until there was no change in weight in a cool, sun-free place. Thereafter, the completely dried dried material was pulverized by using a homogenizer to obtain pulverized products, and 400 g of an extraction solvent was prepared by mixing ethanol and distilled water at a weight ratio of 7: 3, and then 50 g of each of the pulverized products was added. At this time, the mixing ratio of the pulverized material to the extraction solvent was 1: 8 by weight. Next, the extraction solvent mixed with the pulverized product was put into a shaking constant-temperature water bath and stirred at 50 DEG C for 2 hours. The material obtained by extraction was insoluble matter removed at room temperature using Wattman (No. 2) extraction solvent filter paper. Thereafter, the solvent was completely removed while concentrating under reduced pressure in a distillation apparatus equipped with a cooling condenser. The extracts were completely dried and their yields were measured. As a result of the measurement of yield, the swimming rate was 5.82% and the mountain water station was 20%.
실험예 1: 티로시나아제 활성 저해 효과Experimental Example 1: Inhibition of tyrosinase activity
상기 실시예 1에서 얻은 추출물에 대하여 티로시나아제 활성 저해 효과를 측정하였다. 본 실험에서 티로시나아제는 버섯류로부터 추출한 것을 사용하였다 (Sigma-Aldrich, US). 티로시나아제에 기질인 L-티로신 기질의 멜라닌 형성에 근거하여 발색되는 정도를 490nm에서 흡광수치를 측정하는 실험법을 사용하였다. The inhibitory effect of tyrosinase activity on the extract obtained in Example 1 was measured. In this experiment, tyrosinase was extracted from mushrooms (Sigma-Aldrich, US). The degree of color development based on melanin formation of the L-tyrosine substrate, which is a substrate for tyrosinase, was determined by measuring the absorbance at 490 nm.
0.1M 인산 완충용액(Phosphate buffer pH 6.8) 120㎕에 1.5mM L-티로신 40㎕를 넣어 반응용액을 만들었다. 반응용액에 시료액을 20㎕씩 첨가하고 5분간 안정화 시킨 후, 머쉬룸 티로시나제 (100 U/㎖)를 20㎕ 첨가하여 37 ℃에서 10분간 효소반응 시켰다. 대조군에는 시료액 대신 DMSO를 넣었으며, 공시료액에는 시료액 대신 DMSO 및 효소대신 0.1M 인산 완충용액을 첨가하였다. 반응용액을 모두 첨가하여 37 ℃에서 10분간 효소반응 시킨 후, 490nm에서 흡광도를 측정하고 하기 수학식 1에 따라 계산하여 시료의 효소저해활성 정도를 구하였다. 그 결과는 표 1에 나타내었다.To 120 μl of 0.1 M phosphate buffer (Phosphate buffer pH 6.8), 40 μl of 1.5 mM L-tyrosine was added to prepare a reaction solution. After adding 20 μl of the sample solution to the reaction solution and stabilizing for 5 minutes, 20 μl of mushroom tyrosinase (100 U / ml) was added and enzyme reaction was performed at 37 ° C for 10 minutes. In the control group, DMSO was added instead of the sample solution. DMSO and 0.1 M phosphate buffer solution were added to the blank sample instead of the sample solution. The reaction solution was added, and the reaction was allowed to proceed at 37 ° C for 10 minutes. The absorbance at 490 nm was measured and calculated according to the following equation (1) to determine the enzyme inhibitory activity of the sample. The results are shown in Table 1.
[식 1][Formula 1]
상기 표 1의 결과와 같이, 산수국 및 애기수영의 추출물을 농도별로 처리하여 티로시나아제 활성저해 실험을 수행한 결과, 양성대조군인 알부틴과 유사한 범위의 효과를 나타내는 것을 확인하였으며, 본원발명의 조성물이 추출물임을 감안할 때 농도 의존적으로 비교적 높은 티로시나아제 활성저해 효능을 확인할 수 있었다. 또한 애기수영이 산수국보다 더 높은 활성저해 효과를 보임으로, 피부 미백에 더 효과적인 조성물로 사용될 수 있음을 확인하였다.As shown in the above Table 1, the tyrosinase activity inhibition test was carried out by treating the extract of Araliae sativa L. and Swine Swine by concentration, and it was confirmed that the effect was similar to that of arbutin, which is a positive control group. Considering this extract, the tyrosinase activity inhibitory effect was relatively high in a concentration-dependent manner. In addition, it has been confirmed that swine swimming can be used as a more effective composition for skin whitening because it exhibits a higher activity inhibitory effect than that of mountain syrup.
실험예 2: 엘라스타아제 활성 저해 효과Experimental Example 2: Elastase activity inhibitory effect
상기 실시예 1에서 얻은 추출물에 대하여 엘라스타아제 활성 저해 효과를 측정하였다. 본 실험에서 엘라스타아제는 돼지췌장으로부터 추출한 것을 사용하였다 (Sigma-Aldrich, US). 엘라스타아제에 펩티드 기질인 N-석시닐-(Ala)3-p-니트로아닐린의 가수분해를 통해 단위시간당 생성되는 4-니트로아닐린의 방출량의 증가를 엘라스타아제의 활성치로 측정하는 실험법을 사용하였다. The extract obtained in Example 1 was measured for the inhibitory effect of elastase activity. Elastase was extracted from the pig pancreas in this experiment (Sigma-Aldrich, US). N-succinyl- (Ala) 3-p-nitroaniline, which is a peptide substrate of elastase, is used to measure the increase in the amount of 4-nitroaniline produced per unit time by the activity of the elastase Respectively.
0.276 M Trizma-HCl (pH 8.0) 140㎕에 8.8 mM N-석시닐-(Ala)3-p-니트로아닐린을 20㎕ 넣어 반응용액을 만들었다. 반응용액에 시료액을 20㎕씩 첨가하고 5분간 안정화 시킨 후, 엘라스타아제 (2.5 U/㎖)를 20㎕ 첨가하여 37 ℃에서 20분간 효소반응 시켰다. 대조군에는 시료액 대신 DMSO를 넣었으며, 공시료액에는 시료액 대신 DMSO 및 효소대신 BSA용액을 첨가하였다. 반응 후 410㎚에서 흡광도를 측정하였으며, 결과를 하기 수학식 2에 따라 계산하여 시료의 효소저해활성 정도를 구하였다. 그 결과는 표 2에 나타내었다.20 μl of 8.8 mM N-succinyl- (Ala) 3-p-nitroaniline was added to 140 μl of 0.276 M Trizma-HCl (pH 8.0) to prepare a reaction solution. 20 μl of the sample solution was added to the reaction solution, and after stabilization for 5 minutes, 20 μl of elastase (2.5 U / ml) was added and enzyme reaction was carried out at 37 ° C for 20 minutes. In the control group, DMSO was added instead of the sample solution. DMSO was used instead of the sample solution and BSA solution was added to the blank solution instead of the enzyme. After the reaction, the absorbance was measured at 410 nm, and the result was calculated according to the following equation (2) to determine the enzyme inhibition activity of the sample. The results are shown in Table 2.
[식 2][Formula 2]
상기 표 2의 결과와 같이, 산수국 및 애기수영의 추출물을 농도별로 처리하여 엘라스타아제 활성저해 실험을 수행한 결과, 양성대조군인 아데노신과 유사한 범위의 효과를 나타내는 것을 확인하였으며, 본원발명의 조성물이 추출물임을 감안할 때 농도 의존적으로 비교적 높은 엘라스타아제 활성저해 효능을 확인할 수 있었다. 또한 산수국이 애기수영보다 더 높은 활성저해 효과를 보임으로, 주름생성 억제에 더 효과적인 조성물로 사용될 수 있음을 확인하였다.As shown in the results of Table 2, the extract of Araliaceae and Aigi Swim was treated by concentration to examine the activity of inhibiting elastase activity. As a result, it was confirmed that the effect was similar to that of adenosine, which is a positive control, Considering this extract, the efficacy of inhibiting elastase activity, which is relatively high in concentration, could be confirmed. In addition, it was confirmed that the mountaineering plant showed a higher activity inhibitory effect than the baby swimming, and thus it can be used as a composition more effective in inhibiting wrinkle formation.
실험예 3: SOD 활성 효과Experimental Example 3: SOD activity effect
상기 실시예 1에서 얻은 추출물에 대하여 SOD 효소 활성 효과를 측정하였다. 본 실험에서 과산화물제거효소(SOD, Superoxide dismutase) 활성 측정은 SOD Assay 키트를 구매하여 실시하였다(Sigma-Aldrich, US). 산화과정을 통해 생긴 과산화물에 의해 발색하는 WST-포마잔(WST-Formazan)을 420㎚에서 흡광수치를 측정한다. SOD 효소가 활성을 나타낼 때 과산화물이 감소하게 되고 포마잔의 생성이 감소함으로 인해 감소하는 발색정도를 측정해 효소 활성을 구하였다. The SOD enzyme activity of the extract obtained in Example 1 was measured. In this experiment, SOD and Superoxide dismutase activities were measured by SOD Assay Kit (Sigma-Aldrich, US). The WST-Formazan (WST-Formazan), which is developed by the peroxide generated by the oxidation process, is measured at 420 nm. The enzymatic activities of SOD enzymes were determined by measuring the degree of color degradation due to the decrease in peroxides and the decrease in formation of formazan when the enzyme showed activity.
키트의 WST 반응용액 160㎕에 시료액을 20㎕를 첨가하고 5분간 안정화 시킨 후, 효소반응용액을 20㎕ 첨가하여 37 ℃에서 30분간 효소반응 시켰다. 대조군에는 시료액 대신 DMSO를 넣었으며, 공시료액에는 시료액 대신 DMSO 및 효소대신 버퍼를 첨가하였다. 반응 후 420㎚에서 흡광도를 측정하였으며, 결과를 하기 수학식 3에 따라 계산하여 시료의 효소 활성 정도를 구하였다. 그 결과는 표 3에 나타내었다.Twenty microliters of the sample solution was added to 160 占 퐇 of the WST reaction solution of the kit, and after stabilization for 5 minutes, 20 占 퐇 of the enzyme reaction solution was added and the enzyme reaction was carried out at 37 占 폚 for 30 minutes. In the control group, DMSO was added instead of the sample solution. DMSO and buffer instead of enzyme were added to the blank sample instead of the sample solution. The absorbance was measured at 420 nm after the reaction, and the result was calculated according to the following equation (3) to determine the degree of enzyme activity of the sample. The results are shown in Table 3.
[식 3][Formula 3]
상기 표 3의 결과와 같이, 산수국 및 애기수영의 추출물을 농도별로 처리하여 SOD 효소활성 실험을 수행한 결과, 산수국 및 애기수영의 SOD효소 활성 효능을 확인할 수 있었다. 키트를 사용하여 실험한 결과로, 추출물을 처리하지 않은 대조군 대비 농도 의존적으로 높은 SOD 효소 활성 효과를 나타냄을 확인하였다. 애기수영이 산수국보다 더 높은 SOD 활성 효과를 보였으며, 이는 낮은 처리 농도 (50㎍/㎖)에서도 90% 가까이 SOD 효소를 활성화시킴으로, 효과적인 항산화 조성물로 사용될 수 있음을 확인하였다.As shown in the above Table 3, SOD enzymatic activity tests were conducted on the extracts of mountain and southern flounder and swine swimming, and the activity of SOD enzymes was confirmed by SOD and swimming. As a result of the experiment using the kit, it was confirmed that the SOD enzyme activity was highly dependent on the concentration of the extract-treated control group. It was confirmed that swine swimming showed higher SOD activity effect than that of mountain syrup, and it can be used as an effective antioxidant composition by activating SOD enzyme at 90% at low treatment concentration (50 μg / ml).
실험예 4: 총 폴리페놀 함량 분석Experimental Example 4: Analysis of total polyphenol content
10㎎/㎖의 농도로 용해한 추출물 20㎕에 20% 폴린-시오칼토(Folin Ciocalteau)시약을 10 % 탄산 나트륨(Na2CO3)용액을 섞어 140㎕ 및 dH2O 20㎕를 차례로 가하여 상온에서 30분간 반응시킨 후 765㎚에서 흡광도를 측정하였으며, 결과를 하기 수학식 4에 따라 계산하여 시료안의 폴리페놀 함량을 구하였다. 총 폴리페놀 함량은 갈릭산(Gallic Acid)을 표준물질로 정하여 시료와 동일한 방법으로 분석하여 작성한 검량 선으로부터 계산하였다. 그 결과는 표 4에 나타내었다.To 20 μl of the extract dissolved at a concentration of 10 mg / ml were added 140 μl of 20% Folin Ciocalteau reagent and 10% sodium carbonate (Na 2 CO 3 ) solution, and 20 μl of dH 2 O were added in order, After 30 minutes of reaction, the absorbance was measured at 765 nm. The polyphenol content in the sample was calculated by the following formula (4). The total polyphenol content was calculated from the calibration curve prepared by analyzing Gallic Acid in the same manner as the standard material. The results are shown in Table 4.
[식 4][Formula 4]
실험예 5: 총 플라보노이드 함량 분석Experimental Example 5: Analysis of total flavonoid content
10mg/ml의 농도로 용해한 추출물 20㎕에 5% 아질산나트륨 용액(NaNO2) 10㎕를 혼합하여 5분간 반응시키고 염화알루미늄 용액 (AlCl36H2O) 100㎕를 첨가하여 다시 5분간 반응시킨다. 그 후, 1M 수산화나트륨 (NaOH) 50㎕와 섞어 10분간 반응시킨 후 510㎚에서 흡광도를 측정하였으며, 결과를 하기 수학식 5에 따라 계산하여 시료안의 플라보노이드 함량을 구하였다. 총 플라보노이드 함량은 카테킨 (Catechin)을 표준물질로 정하여 시료와 동일한 방법으로 분석하여 작성한 검량 선으로부터 계산하였다. 그 결과는 표 4에 나타내었다.10 μl of 5% sodium nitrite solution (NaNO 2 ) was added to 20 μl of the extract dissolved at a concentration of 10 mg / ml, reacted for 5 minutes, added with 100 μl of aluminum chloride solution (AlCl 36 H 2 O) and reacted again for 5 minutes. Thereafter, 50 μl of 1 M sodium hydroxide (NaOH) was mixed and reacted for 10 minutes, and the absorbance was measured at 510 nm. The content of flavonoid in the sample was calculated by the following formula (5). The total flavonoid content was calculated from the calibration curve prepared by analyzing catechin (catechin) in the same manner as the standard material. The results are shown in Table 4.
[식 5][Formula 5]
제형예 1: 정제의 제조Formulation Example 1: Preparation of tablets
상기 실시예 1에서 얻은 추출물에 대하여 통상의 정제 제조방법에 따라 하기 표 5의 성분을 혼합하고 타정하여 정제를 제조한다.The extracts obtained in Example 1 were mixed with the components shown in Table 5 according to a conventional tablet preparation method and tableted to prepare tablets.
제형예Formulation Example 2: 캡슐제의 제조 2: Preparation of capsules
상기 실시예 1에서 얻은 추출물에 대하여 통상의 캡슐제 제조방법에 따라 하기 표 6의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.The ingredients obtained in Example 1 were mixed with the ingredients shown in Table 6 according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제형예Formulation Example 3: 3: 액제의Liquid 제조 Produce
상기 실시예 1에서 얻은 추출물에 대하여 기호에 적합한 음료 제조방법에 따라서 하기 표 7의 성분을 혼합하고 과병 또는 파우치에 충전하여 액제를 제조한다.The ingredients obtained in Example 1 were mixed with the ingredients listed in Table 7 according to the preferred beverage preparation method, and filled into bottles or pouches to prepare a liquid preparation.
제형예 4: 젤리의 제조Formulation Example 4: Preparation of jelly
상기 실시예 1에서 얻은 추출물에 대하여 기호에 적합한 젤리 제조방법에 따라서 하기 표 8의 성분을 혼합하고 삼면포에 충전하여 젤리를 제조한다.The extracts obtained in Example 1 were mixed with the ingredients shown in Table 8 according to the preferred jelly preparation method, and the jellies were prepared by filling three kinds of jelly.
제형예 5 : 영양크림의 제조Formulation Example 5: Preparation of nutritional cream
상기 실시예 1에서 얻은 추출물에 대하여 영양크림을 통상의 방법에 따라 하기 표 9의 조성으로 제조하였다.Nutritive creams were prepared for the extracts obtained in Example 1 according to the usual methods according to the composition shown in Table 9 below.
상기 제형예들의 실시예 1은 애기수영 추출물, 산수국 추출물, 또는 이들의 혼합 추출물에서 선택되는 어느 것 일 수 있다.Example 1 of the above formulation examples may be any one selected from a baby swimming extract, a mountain juice extract, or a mixed extract thereof.
또한, 상기의 조성비는 일반적으로 적합한 성분을 혼합하여 제형예로 조성하였지만, 필요에 따라서 그 배합비 및 원료를 임의로 변경 실시하여도 무방하다. In addition, although the above-mentioned composition ratio is generally prepared by mixing a suitable component, it is also possible to arbitrarily change the compounding ratio and the raw material as necessary.
본 발명의 추출물은 모든 제형예 시험 조건에서 안정하므로 제형의 안정성에는 문제가 없었다.The extract of the present invention was stable in all formulation test conditions and therefore had no problem in the stability of the formulation.
Claims (7)
A composition for improving wrinkles and skin whitening comprising Hydrangea serrata extract of water, ethanol or a mixed solvent thereof as an active ingredient.
The composition for improving wrinkles and skin whitening according to claim 1, wherein the composition comprises 0.001 to 80% by weight based on the total weight of the composition.
The composition according to claim 1, wherein the composition exhibits a wrinkle-reducing effect by inhibiting elastase.
The composition according to claim 1, wherein the composition exhibits a skin whitening effect by inhibiting tyrosinase.
The composition according to claim 1, wherein the composition has one or more formulations selected from the group consisting of tablets, granules, pills, capsules, liquids, jellies or gums, Composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160062854A KR101936294B1 (en) | 2016-05-23 | 2016-05-23 | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160062854A KR101936294B1 (en) | 2016-05-23 | 2016-05-23 | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170132388A KR20170132388A (en) | 2017-12-04 |
KR101936294B1 true KR101936294B1 (en) | 2019-01-08 |
Family
ID=60921453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160062854A KR101936294B1 (en) | 2016-05-23 | 2016-05-23 | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101936294B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200098042A (en) | 2019-02-11 | 2020-08-20 | 코스맥스바이오 주식회사 | A composition for inhibiting fatty formation and reducing body fat comprising of hydrangenol as an active ingredient |
KR20230064369A (en) | 2021-11-03 | 2023-05-10 | 동의대학교 산학협력단 | Composition for skin whitening and wrinkle improvement containing saussurea neoserrata extract |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101946526B1 (en) * | 2017-12-19 | 2019-02-11 | 코스맥스바이오 주식회사 | Composition of preventing or improving UV-induced skin damage comprising hydrangenol |
KR102141039B1 (en) * | 2017-12-20 | 2020-08-05 | 재단법인 홍천메디칼허브연구소 | Compositions for preventing or treating Psoriasis comprising extract of Rumex acetosella |
KR102313083B1 (en) * | 2018-11-19 | 2021-10-18 | 제주대학교 산학협력단 | An anti-oxidative composition comprising an extract of Hydrangea petiolaris or a fraction thereof as an active ingredient |
KR102173731B1 (en) | 2020-08-12 | 2020-11-03 | 계명대학교 산학협력단 | Composition for Improving Wrinkle, Wound Healing, Cosmetic Surgery, Treating Hair Loss, or Stimulating Hair Growth Comprising Protein Hydrolysate of larva of Tenebrio molitor |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003246722A (en) | 2002-02-25 | 2003-09-02 | Kanebo Ltd | Whitening cosmetic |
KR100667448B1 (en) * | 2005-09-01 | 2007-01-10 | 주식회사 쵸이스코스메틱 | Cosmetic composition containing a gynostemma pentaphyllum makino extract |
JP2011246353A (en) | 2010-05-22 | 2011-12-08 | Pola Chemical Industries Inc | Skin external preparation |
-
2016
- 2016-05-23 KR KR1020160062854A patent/KR101936294B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003246722A (en) | 2002-02-25 | 2003-09-02 | Kanebo Ltd | Whitening cosmetic |
KR100667448B1 (en) * | 2005-09-01 | 2007-01-10 | 주식회사 쵸이스코스메틱 | Cosmetic composition containing a gynostemma pentaphyllum makino extract |
JP2011246353A (en) | 2010-05-22 | 2011-12-08 | Pola Chemical Industries Inc | Skin external preparation |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200098042A (en) | 2019-02-11 | 2020-08-20 | 코스맥스바이오 주식회사 | A composition for inhibiting fatty formation and reducing body fat comprising of hydrangenol as an active ingredient |
KR20230064369A (en) | 2021-11-03 | 2023-05-10 | 동의대학교 산학협력단 | Composition for skin whitening and wrinkle improvement containing saussurea neoserrata extract |
Also Published As
Publication number | Publication date |
---|---|
KR20170132388A (en) | 2017-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101936294B1 (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
KR101902911B1 (en) | Composition for improving human skin cell injury by UV-B comprising the extract of Hydrangea serrata | |
KR20090080153A (en) | Composition for wrinkle-care and skin-whitening | |
KR102253095B1 (en) | Cosmetic composition for improving acned skin, Manufacturing method thereof and functional cosmetics for improving acned skin containing the same | |
KR101292837B1 (en) | Composition for skin wrinkle improvement comprising extracts of Junglans mandshurica MAXIM as an active ingredient | |
KR101182032B1 (en) | Composition comprising the essential oil extract of Laminaria japonica showing anti-oxidant activity | |
KR20130010250A (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
KR102236071B1 (en) | Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater | |
KR20100121352A (en) | A composition comprising complex crude drug extract for anti-aging and improvement of skin | |
KR101954275B1 (en) | Cosmetic compositions containing complex extract of gold kiwi peel and dragon fruit peel, and method manufacturing the same | |
KR20140068679A (en) | Composition comprising extracts of white tea for the care of skin wrinkle | |
KR101447007B1 (en) | Composition for antiaging comprising the extract of Dipterocarpus obtusifolius Teijsm. Ex Miq. as an active ingredient | |
KR101182059B1 (en) | Composition comprising the essential oil extract of hizikia fusiforme showing anti-oxidant activity | |
KR102370528B1 (en) | Compositions containing Beta vulgaris fermentation extract | |
KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR102128168B1 (en) | Composition comprising the extract of Lentinula edodes and Acer pictum subsp. mono leaf for antioxidant effect | |
KR101249034B1 (en) | Composition for skin wrinkle improvement and whitening comprising extracts of Coriandum sativum. L as an active ingredient | |
CN113631227A (en) | Antiaging agent, antioxidant, antiinflammatory agent, whitening agent, and cosmetic | |
KR102590758B1 (en) | Antioxidant or anti-inflammatory composition comprising extract of bilberry containing anthocyanidin components | |
KR102401490B1 (en) | Compositions containing Angelica gigas extract | |
KR102355138B1 (en) | Composition for whitening or anti-wrinkle of the skin comprising fermentated ziziphus jujuba seed as effective component | |
KR102313083B1 (en) | An anti-oxidative composition comprising an extract of Hydrangea petiolaris or a fraction thereof as an active ingredient | |
KR102014960B1 (en) | Composition for anti oxidation containing extract of soybean root | |
KR102609952B1 (en) | Ample type cosmetic composition improving skin elasticity, Manufacturing method of the same and Ample type comsmetics improving skin elasticity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |